413 related articles for article (PubMed ID: 29660934)
1. Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.
Meyer PF; Savard M; Poirier J; Labonté A; Rosa-Neto P; Weitz TM; Town T; Breitner J; ;
J Alzheimers Dis; 2018; 63(2):577-590. PubMed ID: 29660934
[TBL] [Abstract][Full Text] [Related]
2. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
5. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
6. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
7. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ;
Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940
[TBL] [Abstract][Full Text] [Related]
10. Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.
Meyer PF; Savard M; Poirier J; Morgan D; Breitner J;
Alzheimers Dement; 2019 Sep; 15(9):1160-1171. PubMed ID: 31405825
[TBL] [Abstract][Full Text] [Related]
11. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
[TBL] [Abstract][Full Text] [Related]
13. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
14. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
[TBL] [Abstract][Full Text] [Related]
15. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
[TBL] [Abstract][Full Text] [Related]
16. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
17. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.
Voyle N; Patel H; Folarin A; Newhouse S; Johnston C; Visser PJ; Dobson RJ; Kiddle SJ;
J Alzheimers Dis; 2017; 55(4):1417-1427. PubMed ID: 27834776
[TBL] [Abstract][Full Text] [Related]
18. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
Wang ML; Wei XE; Yu MM; Li PY; Li WB;
Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
[TBL] [Abstract][Full Text] [Related]
19. CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers.
Ayton S; Janelidze S; Kalinowski P; Palmqvist S; Belaidi AA; Stomrud E; Roberts A; Roberts B; Hansson O; Bush AI
J Neurol Neurosurg Psychiatry; 2023 Mar; 94(3):211-219. PubMed ID: 36357168
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
